TR200102107T2 - Tümör nekroz faktör antagonistleri ve endometriozda kullanımları. - Google Patents

Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.

Info

Publication number
TR200102107T2
TR200102107T2 TR2001/02107T TR200102107T TR200102107T2 TR 200102107 T2 TR200102107 T2 TR 200102107T2 TR 2001/02107 T TR2001/02107 T TR 2001/02107T TR 200102107 T TR200102107 T TR 200102107T TR 200102107 T2 TR200102107 T2 TR 200102107T2
Authority
TR
Turkey
Prior art keywords
necrosis factor
tumor necrosis
antagonists
endometriosis
factor antagonists
Prior art date
Application number
TR2001/02107T
Other languages
English (en)
Inventor
Borrelli Francesco
D'antonio Mauro
Martelli Fabrizizio
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102107(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200102107T2 publication Critical patent/TR200102107T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tümör nekroz faktör antagonistleri endometriozu tedavi etmek ve/veya önlemek için terapötik olarak etkili dozlarda verilirler. Bu bulusun antagonistleri tipik olarak çesitli sinif moleküller arasindan seçilir fakat tercihen çözünür TNF reseptörleridir. Antagonistler; endometriotik yaralarin iyilesmesi için ve eger baska aktif karisimdaki maddeler ile birlesirse kisirlik gibi alakali rahatsizliklarin iyilesmesi için yararlidirlar.
TR2001/02107T 1999-01-22 2000-01-19 Tümör nekroz faktör antagonistleri ve endometriozda kullanımları. TR200102107T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
TR200102107T2 true TR200102107T2 (tr) 2001-12-21

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02107T TR200102107T2 (tr) 1999-01-22 2000-01-19 Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.

Country Status (30)

Country Link
US (2) US6663865B1 (tr)
EP (2) EP1022027A1 (tr)
JP (1) JP4601176B2 (tr)
KR (2) KR20060128056A (tr)
CN (2) CN1212152C (tr)
AR (1) AR022251A1 (tr)
AT (1) ATE242002T1 (tr)
AU (1) AU771964B2 (tr)
BG (1) BG65556B1 (tr)
BR (1) BR0008182A (tr)
CA (1) CA2356737C (tr)
CZ (1) CZ302866B6 (tr)
DE (1) DE60003152T2 (tr)
DK (1) DK1143997T3 (tr)
EA (1) EA003927B1 (tr)
EE (1) EE05543B1 (tr)
ES (1) ES2200808T3 (tr)
HK (2) HK1043059B (tr)
HU (1) HU226149B1 (tr)
IL (2) IL144413A0 (tr)
NO (1) NO328814B1 (tr)
NZ (1) NZ512585A (tr)
PL (1) PL204713B1 (tr)
PT (1) PT1143997E (tr)
SI (1) SI1143997T1 (tr)
SK (1) SK287313B6 (tr)
TR (1) TR200102107T2 (tr)
UA (1) UA78483C2 (tr)
WO (1) WO2000043031A1 (tr)
ZA (1) ZA200105263B (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100857376B1 (ko) * 2001-01-29 2008-09-05 라보라토리스 세로노 에스.에이. 심장 질환의 치료 및/또는 예방에 사용되는 ｉｌ-18저해물질
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060258568A1 (en) * 2003-02-07 2006-11-16 Austia Wirtschaftsservice Gesellschaft Mit Beschrankter Use of human chorionic gonadotropin in the treatment in the treatment of symptoms endometriosis
MXPA06002853A (es) 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
JP2008501035A (ja) * 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
EP2446887A3 (en) * 2005-07-12 2012-08-15 DMI Biosciences, Inc. Use of danazol for the treatment of Alzheimer's disease
US8877186B2 (en) * 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
PT2554171E (pt) 2009-06-22 2014-11-06 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
CA2978449A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
DE69231828T3 (de) * 1991-03-18 2008-06-19 New York University Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
ZA200105263B (en) 2002-06-26
SK10292001A3 (sk) 2001-12-03
HU226149B1 (en) 2008-05-28
CN1698894A (zh) 2005-11-23
AU1997300A (en) 2000-08-07
DK1143997T3 (da) 2003-09-15
CN100594932C (zh) 2010-03-24
EA200100799A1 (ru) 2001-12-24
IL144413A (en) 2009-05-04
ATE242002T1 (de) 2003-06-15
ES2200808T3 (es) 2004-03-16
EE05543B1 (et) 2012-06-15
PT1143997E (pt) 2003-10-31
EP1143997A1 (en) 2001-10-17
AR022251A1 (es) 2002-09-04
SK287313B6 (sk) 2010-06-07
BG105691A (en) 2002-02-28
JP2002535284A (ja) 2002-10-22
NZ512585A (en) 2003-08-29
HK1043059A1 (en) 2002-09-06
HUP0105103A3 (en) 2004-08-30
HK1082690A1 (en) 2006-06-16
CZ20012656A3 (cs) 2002-02-13
JP4601176B2 (ja) 2010-12-22
US6663865B1 (en) 2003-12-16
US20040057954A1 (en) 2004-03-25
BG65556B1 (bg) 2008-12-30
WO2000043031A1 (en) 2000-07-27
PL204713B1 (pl) 2010-02-26
NO328814B1 (no) 2010-05-18
UA78483C2 (en) 2007-04-10
DE60003152D1 (de) 2003-07-10
IL144413A0 (en) 2002-05-23
HUP0105103A2 (hu) 2002-04-29
BR0008182A (pt) 2001-11-06
KR20010101397A (ko) 2001-11-14
CN1337883A (zh) 2002-02-27
HK1043059B (zh) 2005-11-18
EE200100378A (et) 2002-10-15
SI1143997T1 (en) 2003-12-31
EA003927B1 (ru) 2003-10-30
KR100685106B1 (ko) 2007-02-22
DE60003152T2 (de) 2004-03-25
CA2356737C (en) 2010-03-23
CZ302866B6 (cs) 2011-12-21
CA2356737A1 (en) 2000-07-27
KR20060128056A (ko) 2006-12-13
EP1143997B1 (en) 2003-06-04
PL350002A1 (en) 2002-10-21
AU771964B2 (en) 2004-04-08
CN1212152C (zh) 2005-07-27
NO20013577D0 (no) 2001-07-19
EP1022027A1 (en) 2000-07-26
NO20013577L (no) 2001-08-29

Similar Documents

Publication Publication Date Title
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
TR199901417T2 (tr) Analjezik etkisi olan yeni bilesimler.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
TR200000913T2 (tr) Tıbbi maddeler
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
TR200103271T2 (tr) İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi.
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
TR200102041T2 (tr) Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar
ATE474572T1 (de) Heilung von wunden
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular